Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
Phase: PHASE1 | Sponsor: Yale University | Compound: Psilocybin
- Status
- recruiting
- Institution
- Yale University
- Start date
- 2024-10-17
- End date
- 2027-12-01
- Registry ID
- NCT06442423
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.